GlassScriptPhysician profile
Bruce S Trippe
NPI 1700936200
$68,064.76
in general payments reported to CMS, 2019-2025
47 companies · $704 in 2025
The $704 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $13K · 2021: $5,544 · 2022: $1,352 · 2023: $6,282 · 2024: $6,176 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,432 · Consulting Fee: $5,100 · Food and Beverage: $2,629 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,431.80 |
| Consulting Fee | $5,100.00 |
| Food and Beverage | $2,628.75 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $22,104.65 | 2019-2023 | |
| Ibsa Pharma INC. | $16,251.30 | 2019-2024 | Tirosint, Tirosint, Licart |
| Mannkind Corporation | $7,544.30 | 2019-2023 | Afrezza |
| Novo Nordisk INC | $5,166.51 | 2019-2025 | Ozempic, Rybelsus |
| Alfasigma USA, INC. | $3,688.37 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $3,430.79 | 2019-2021 | |
| Medicure Pharma INC. | $3,000.00 | 2019 | |
| Lilly USA, LLC | $1,585.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $630.93 | 2019-2022 | |
| Corcept Therapeutics | $569.39 | 2019-2024 | Korlym |
| Esperion Therapeutics, INC. | $553.93 | 2021-2025 | Nexletol |
| Dexcom, INC. | $352.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.78 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $259.48 | 2019-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $240.73 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Trippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.